why are glp 1 meds so expensive GLP-1 medications in the U.S.? Why obesity GLP-1 drugs are
Description
Similar content being viewed by others 1 Introduction Semaglutide (US brand name Ozempic or Wegovy), a Glucagon-like peptide-1 receptor (GLP-1R) agonist containing the active ingredient semaglutide, is approved by the Food and Drug Administration for its potential therapeutic role in obesity and diabetes mellitus (DM) similar to other agonists within the GLP-1R family such as liraglutide
Obesity is a chronic condition, and your prescription medication is a tool for long-term management
Wegovy is a brand name for semaglutide, the same active ingredient in Ozempic, prescribed specifically for chronic weight management
doi:10.1111/dom.14640 56
The important action of semaglutide through GLP-1 enhancement is the inhibition of glucagon release from pancreatic -cells, decreasing hepatic gluconeogenesis and maintaining glucose stability, especially postprandially [40,47]
Ozempic is the brand name for an injectable form of semaglutide thats approved for treating type 2 diabetes
